Therefore, it is of interest to assess the correlation ofCYP1A1, CYP1B1, CYP2C genotypes with treatment efficacy and clinical outcomes in breast cancer patients administered with doxorubicinand paclitaxel based chemotherapy. Here, CYP2C9 is linked to breast carcinoma.